RxDoctor Payments Data

Bruce Haffty, MD

Radiation Oncology · New Brunswick, NJNPI 1033108782

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,000 of the $1,401 with a category attached, or 71.4%. Accuray Incorporated accounts for 71.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $1,000 and has fallen 69.9% since, to $301 in 2025.

$1,401in general payments, 2019–2025

Across 7 payments — averaging $200.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Accuray Incorporated$1K
  • Novocure Inc.$161
  • Elekta, Inc.$141
  • Mevion_medical_systems_inc$64
  • Novartis$19
  • Daiichi Sankyo Inc.$17
$79,999in research payments, 2019–2025

Across 2 payments — averaging $40,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • BTG International Inc.$80K

What the payments were for

  • Speaking & faculty fees$1,00071%
  • Food & beverage$40129%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Accuray Incorporated1$1,000
Novocure Inc.1$161
Elekta, Inc.1$141
Mevion_medical_systems_inc2$64
Novartis1$19
Daiichi Sankyo Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,401 in reported general payments places this provider in the 70th percentile of 132 radiation oncology providers in New Jersey.

See all radiation oncology providers in New Jersey

Medicare billing

Part B allowed, 2024
$48,312
Medicare patients
135
Services billed
597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other radiation oncology in New Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →